» Articles » PMID: 29692608

Increased Matrix Metalloproteinase-9 to Tissue Inhibitor of Metalloproteinase-1 Ratio in Smokers with Airway Hyperresponsiveness and Accelerated Lung Function Decline

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2018 Apr 26
PMID 29692608
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Airway hyperresponsiveness (AHR) is associated with airway inflammation and a rapid decline in lung function and is a predictor of future risk of COPD among smokers. Alveolar macrophages (AMs) from patients with COPD release a greater amount of matrix metalloproteinase (MMP)-9. We hypothesized that the imbalance between MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) is related to AHR in smokers.

Patients And Methods: Healthy smokers with AHR (AHR + S) or smokers without AHR (AHR - S; divided according to a methacholine challenge test) and nonsmokers without AHR (AHR - NS) were enrolled. Spirometry was performed during enrollment and repeated after 5 years. Initially, AMs recovered from bronchoalveolar lavage (BAL) fluid were cultured in the presence of p38 mitogen-activated protein kinase (MAPK) inhibitor (SB203580), MAPK kinase (MEK) 1/2 (the MEK of extracellular signal-regulated kinase [ERK] inhibitor, PD98059), or medium alone for 24 h. The release of MMP-9 and TIMP-1 in culture supernatants was measured by enzyme-linked immunosorbent assay.

Results: A greater reduction in forced expiratory volume in 1 s (FEV)/forced vital capacity (FVC), FEV (as a percentage of the predicted value [%pred]), and maximal mid-expiratory flow (MMEF) was observed among AHR + S in the 5-year period. There was a higher proportion of neutrophils and a lower proportion of AMs in BAL fluid recovered from AHR + S. Compared to AMs from AHR - NS and AHR - S, AMs from nonsmokers with AHR (AHR + NS) released more MMP-9 and less TIMP-1, with an increase in MMP-9/TIMP-1 ratios. The MMP-9/TIMP-1 ratio in smokers was positively correlated with the annual decline in FEV%pred, FVC%pred, and MMEF%pred. Both SB203580 and PD98059 significantly reduced MMP-9, but not TIMP-1, from AMs of smokers.

Conclusion: AMs of AHR + NS produce excessive MMP-9 over TIMP-1, which may be a predictor of the development of airway obstruction. Inhibition of p38 MAPK and ERK suppresses the generation of MMP-9 by AMs from smokers.

Citing Articles

IL-6 and TIMP-1 Correlated to Airway Pathogen Colonization and Predict Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis.

Lin H, Hsieh M, Lo Y, Huang H, Huang S, Huang C J Inflamm Res. 2024; 17:5701-5709.

PMID: 39219819 PMC: 11366244. DOI: 10.2147/JIR.S465413.


TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases.

Almuntashiri S, Alhumaid A, Zhu Y, Han Y, Dutta S, Khilji O Chin Med J Pulm Crit Care Med. 2024; 1(2):67-76.

PMID: 38343891 PMC: 10857872. DOI: 10.1016/j.pccm.2023.05.002.


p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.

Ahmadi A, Ahrari S, Salimian J, Salehi Z, Karimi M, Emamvirdizadeh A Cell Commun Signal. 2023; 21(1):314.

PMID: 37919729 PMC: 10623820. DOI: 10.1186/s12964-023-01337-4.


Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia.

Zingaropoli M, Latronico T, Pasculli P, Masci G, Merz R, Ciccone F Biomolecules. 2023; 13(7).

PMID: 37509076 PMC: 10377146. DOI: 10.3390/biom13071040.


A2M Serves as Promising Biomarker for Chronic Obstructive Pulmonary Disease.

Xiao X, Cai W, Ding Z, Shi Y, Fan L, Zhang Q Int J Chron Obstruct Pulmon Dis. 2023; 18:683-692.

PMID: 37123074 PMC: 10145514. DOI: 10.2147/COPD.S407491.


References
1.
Popa V . ATS guidelines for methacholine and exercise challenge testing. Am J Respir Crit Care Med. 2001; 163(1):292-3. DOI: 10.1164/ajrccm.163.1.16310b. View

2.
Frew A, Kennedy S, Chan-Yeung M . Methacholine responsiveness, smoking, and atopy as risk factors for accelerated FEV1 decline in male working populations. Am Rev Respir Dis. 1992; 146(4):878-83. DOI: 10.1164/ajrccm/146.4.878. View

3.
Walker P, Hadcroft J, Costello R, Calverley P . Lung function changes following methacholine inhalation in COPD. Respir Med. 2008; 103(4):535-41. DOI: 10.1016/j.rmed.2008.11.002. View

4.
Barnes P . Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacol Rev. 2016; 68(3):788-815. DOI: 10.1124/pr.116.012518. View

5.
Lei Y, Gao Y, Chen J, Li M, Wu X, Ning Q . GLCCI1 rs37973: a potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese chronic obstructive pulmonary disease patients. Sci Rep. 2017; 7:42552. PMC: 5301211. DOI: 10.1038/srep42552. View